News

Time a significant factor in assessing RA patients’ symptoms


 

References

Reliability of patient-reported outcomes for pain, fatigue, and other disease activity measurements in rheumatoid arthritis patients decreased as time intervals between assessments increased, according to research published in Rheumatology.

It is unclear to what degree variability between the measurements is explainable by within-patient variability and measurement error, reported Dr. Paul Studenic of the Medical University of Vienna (Austria) and his associates.

©Suze777/Thinkstock.com

They assessed 40 rheumatoid arthritis patients and gathered self-assessed pain, fatigue, and patient global assessment (PGA) scores three times per day for 2 months. Twenty patients recorded their assessments over the phone, and 20 kept a diary. PGA was assessed on a 100-mm visual analog scale (VAS), using no disease activity and highly active disease as anchors. The investigators calculated intraclass correlation coefficients (ICCs) and the smallest detectable differences (SDDs) for 1-, 7-, 14- and 28-day testing intervals.

Overall, the SDD and ICC were 25 mm and 0.67 for pain, 25 mm and 0.71 for PGA, and 30 mm and 0.66 for fatigue, respectively. SDD was higher with longer time periods between assessments, ranging from 19 mm (1-day intervals) to 30 mm (28-day intervals) for pain, 19-33 mm for PGA, and 26-34 mm for fatigue. Meanwhile, ICC was smaller with longer intervals, and ranged between the 1- and the 28-day interval from 0.80 to 0.50 for pain, 0.83 to 0.57 for PGA, and 0.76 to 0.58 for fatigue. In general, higher reliability according to ICC coincided with smaller SDD. The researchers noted that pain scores had a significant effect on the patient’s estimation of disease activity.

“The results of this study suggest that, in stable RA patients, a 25-mm change on the VAS for pain or PGA and a 30-mm change for fatigue may identify true change; however, this is clearly dependent on (and can be refined based on) the starting measurement level. It is also apparent that in patients who are assessed less frequently, the evaluation of measurement differences as indicating changes is more difficult,” the investigators concluded.

Read the full article here.

mbock@frontlinemedcom.com

Recommended Reading

EULAR: Baricitinib shows RA efficacy in two trials
MDedge Rheumatology
FDA will strengthen heart attack, stroke risk warnings for all NSAIDs
MDedge Rheumatology
Pain, quality of life measures improve more in OA than RA after knee arthroplasty
MDedge Rheumatology
Recommended RA targets tied to better health outcomes
MDedge Rheumatology
Study links statin use to lower mortality in RA patients
MDedge Rheumatology
Yet another insurer demand: patient care notifications
MDedge Rheumatology
Predictors identified for progression of moderate RA on methotrexate
MDedge Rheumatology
OCs may ease inflammatory arthritis severity
MDedge Rheumatology
Long-term RA remission can restore physical function
MDedge Rheumatology
Tofacitinib proves effective in RA when biologics don’t work
MDedge Rheumatology